Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that as of July 1, 2024, it has entered into an agreement with Apexus to make IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3% and other Harrow products available through its 340B Prime Vendor Program. IHEEZO, indicated for ocular anesthesia, is a low-viscosity topical ocular anesthetic gel with reliable efficacy, a proven safety profile, and simple administ